Advertisement
Screener

Spero Therapeutics, Inc. (SPRO) Increase (Decrease) in Accounts Payable

2.8 / 5 stars · 68/120 Roast Me

Spero Therapeutics, Inc. Increase (Decrease) in Accounts Payable

Spero Therapeutics, Inc. (SPRO) reported Increase (Decrease) in Accounts Payable of -$538.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-12

  • Spero Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$62.00K.
  • Spero Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$476.00K.
  • Spero Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$702.00K, a 157.73% decline year-over-year.
  • Spero Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $615.00K, a 81.88% decline year-over-year.
  • Spero Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2025 was -$6.61M, a 211.56% decline from fiscal 2024.
  • Spero Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2024 was $5.93M, a 678.98% increase from fiscal 2023.
  • Spero Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2023 was $761.00K.
  • Spero Therapeutics, Inc. increase (decrease) in accounts payable for fiscal 2022 was -$484.00K.
Period endIncrease (Decrease) in Accounts Payable 3 monthIncrease (Decrease) in Accounts Payable 6 monthIncrease (Decrease) in Accounts Payable 9 monthIncrease (Decrease) in Accounts Payable 12 month
2026-06-30-$62.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$538.00K
10-Q · filed 2026-08-12
-$1.24M
derived: sum of 3 quarters · filed 2026-08-12
-$625.00K
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$476.00K
10-Q · filed 2026-05-13
-$1.18M
derived: sum of 2 quarters · filed 2026-05-13
-$563.00K
derived: sum of 3 quarters · filed 2026-05-13
-$1.55M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31-$702.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
-$87.00K
derived: sum of 2 quarters · filed 2026-03-26
-$1.07M
derived: sum of 3 quarters · filed 2026-08-12
-$6.61M
10-K · filed 2026-03-26
2025-09-30$615.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
-$370.00K
derived: sum of 2 quarters · filed 2026-08-12
-$5.91M
10-Q · filed 2025-11-13
-$4.70M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30-$985.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12
-$6.53M
10-Q · filed 2026-08-12
-$5.31M
derived: sum of 3 quarters · filed 2026-08-12
-$1.92M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$5.54M
10-Q · filed 2026-05-13
-$4.33M
derived: sum of 2 quarters · filed 2026-05-13
-$931.00K
derived: sum of 3 quarters · filed 2026-05-13
-$1.30M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$1.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26
$4.61M
derived: sum of 2 quarters · filed 2026-03-26
$4.24M
derived: sum of 3 quarters · filed 2026-03-26
$5.93M
10-K · filed 2026-03-26
2024-09-30$3.39M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$3.02M
derived: sum of 2 quarters · filed 2025-11-13
$4.71M
10-Q · filed 2025-11-13
$4.99M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$370.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12
$1.32M
10-Q · filed 2025-08-12
$1.59M
derived: sum of 3 quarters · filed 2025-08-12
$1.39M
derived: sum of 4 quarters · filed 2025-08-12
2024-03-31$1.69M
10-Q · filed 2025-05-13
$1.96M
derived: sum of 2 quarters · filed 2025-05-13
$1.76M
derived: sum of 3 quarters · filed 2025-05-13
$2.48M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31$275.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27
$68.00K
derived: sum of 2 quarters · filed 2025-03-27
$795.00K
derived: sum of 3 quarters · filed 2025-03-27
$761.00K
10-K · filed 2025-03-27
2023-09-30-$207.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$520.00K
derived: sum of 2 quarters · filed 2024-11-14
$486.00K
10-Q · filed 2024-11-14
-$1.48M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$727.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05
$693.00K
10-Q · filed 2024-08-05
-$1.27M
derived: sum of 3 quarters · filed 2024-08-05
-$403.00K
derived: sum of 4 quarters · filed 2024-08-05
2023-03-31-$34.00K
10-Q · filed 2024-05-15
-$2.00M
derived: sum of 2 quarters · filed 2024-05-15
-$1.13M
derived: sum of 3 quarters · filed 2024-05-15
-$4.20M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31-$1.97M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13
-$1.10M
derived: sum of 2 quarters · filed 2024-03-13
-$4.16M
derived: sum of 3 quarters · filed 2024-03-13
-$484.00K
10-K · filed 2024-03-13
2022-09-30$871.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$2.20M
derived: sum of 2 quarters · filed 2023-11-13
$1.48M
10-Q · filed 2023-11-13
-$577.00K
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$3.07M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
$612.00K
10-Q · filed 2023-08-10
-$1.45M
derived: sum of 3 quarters · filed 2023-08-10
$81.00K
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$3.68M
10-Q · filed 2023-05-11
$1.62M
derived: sum of 2 quarters · filed 2023-05-11
$3.15M
derived: sum of 3 quarters · filed 2023-05-11
$937.00K
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31-$2.06M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$531.00K
derived: sum of 2 quarters · filed 2023-03-30
-$2.74M
derived: sum of 3 quarters · filed 2023-03-30
-$53.00K
10-K · filed 2023-03-30
2021-09-30$1.53M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
-$682.00K
derived: sum of 2 quarters · filed 2022-11-14
$2.01M
10-Q · filed 2022-11-14
$688.00K
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$2.21M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
$478.00K
10-Q · filed 2022-08-10
-$841.00K
derived: sum of 3 quarters · filed 2022-08-10
$70.00K
derived: sum of 4 quarters · filed 2022-08-10
2021-03-31$2.69M
10-Q · filed 2022-05-16
$1.37M
derived: sum of 2 quarters · filed 2022-05-16
$2.28M
derived: sum of 3 quarters · filed 2022-05-16
-$5.11M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31-$1.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
-$408.00K
derived: sum of 2 quarters · filed 2022-03-31
-$7.80M
derived: sum of 3 quarters · filed 2022-03-31
-$2.98M
10-K · filed 2022-03-31
2020-09-30$911.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$6.48M
derived: sum of 2 quarters · filed 2021-11-10
-$1.66M
10-Q · filed 2021-11-10
-$51.00K
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$7.39M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
-$2.57M
10-Q · filed 2021-08-05
-$962.00K
derived: sum of 3 quarters · filed 2021-08-05
$523.00K
derived: sum of 4 quarters · filed 2021-08-05
2020-03-31$4.82M
10-Q · filed 2021-05-06
$6.43M
derived: sum of 2 quarters · filed 2021-05-06
$7.91M
derived: sum of 3 quarters · filed 2021-05-06
$8.40M
derived: sum of 4 quarters · filed 2021-05-06
2019-12-31$1.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11
$3.09M
derived: sum of 2 quarters · filed 2021-03-11
$3.57M
derived: sum of 3 quarters · filed 2021-03-11
$564.00K
10-K · filed 2021-03-11
2019-09-30$1.49M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$1.97M
derived: sum of 2 quarters · filed 2020-11-05
-$1.04M
10-Q · filed 2020-11-05
$1.13M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$482.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
-$2.53M
10-Q · filed 2020-08-06
-$354.00K
derived: sum of 3 quarters · filed 2020-08-06
$305.00K
derived: sum of 4 quarters · filed 2020-08-06
2019-03-31-$3.01M
10-Q · filed 2020-05-08
-$836.00K
derived: sum of 2 quarters · filed 2020-05-08
-$177.00K
derived: sum of 3 quarters · filed 2020-05-08
-$455.00K
derived: sum of 4 quarters · filed 2020-05-08
2018-12-31$2.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
$2.83M
derived: sum of 2 quarters · filed 2020-03-16
$2.55M
derived: sum of 3 quarters · filed 2020-03-16
$84.00K
10-K · filed 2020-03-16
2018-09-30$659.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-04
$381.00K
derived: sum of 2 quarters · filed 2019-11-04
-$2.09M
10-Q · filed 2019-11-04
$373.00K
derived: sum of 4 quarters · filed 2019-11-04
2018-06-30-$278.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
-$2.75M
10-Q · filed 2019-08-08
-$286.00K
derived: sum of 3 quarters · filed 2019-08-08
-$516.00K
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31-$2.47M
10-Q · filed 2019-05-09
-$8.00K
derived: sum of 2 quarters · filed 2019-05-09
-$238.00K
derived: sum of 3 quarters · filed 2019-05-09
-$38.00K
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$2.46M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14
$2.23M
derived: sum of 2 quarters · filed 2019-03-14
$2.43M
derived: sum of 3 quarters · filed 2019-03-14
$2.35M
10-K · filed 2019-03-14
2017-09-30-$230.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
-$30.00K
derived: sum of 2 quarters · filed 2018-11-08
-$112.00K
10-Q · filed 2018-11-08
-$77.00K
derived: sum of 4 quarters · filed 2019-03-14
2017-06-30$200.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$118.00K
10-Q · filed 2018-08-09
$153.00K
derived: sum of 3 quarters · filed 2019-03-14
2017-03-31-$82.00K
10-Q · filed 2018-05-10
-$47.00K
derived: sum of 2 quarters · filed 2019-03-14
2016-12-31$35.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14
-$644.00K
10-K · filed 2019-03-14
2016-09-30-$679.00K
10-Q · filed 2017-12-14
2015-12-31$671.00K
10-K · filed 2018-04-02

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cingulate Inc. (CING)United States$0.073B-2.64
Lunai Bioworks Inc. (LNAI)United States$0.072B-0.11
Aldeyra Therapeutics, Inc. (ALDX)United States$0.074B-5.57
PMV Pharmaceuticals, Inc. (PMVP)United States$0.071B-0.95
TENAX THERAPEUTICS, INC. (TENX)United States$0.071B-7.17
PLIANT THERAPEUTICS, INC. (PLRX)United States$0.071B-0.76
Yarrow Bioscience, Inc. (YARW)United States$0.070B
OS Therapies Inc (OSTX)United States$0.076B-2.17
Verrica Pharmaceuticals Inc. (VRCA)United States$0.076B-3.39
Connect Biopharma Holdings Ltd (CNTB)$0.069B-2.17